Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report released on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Bellerophon Therapeutics stock opened at $0.01 on Wednesday. Bellerophon Therapeutics has a 52 week low of $0.01 and a 52 week high of $0.02. The stock has a 50-day simple moving average of $0.04 and a 200 day simple moving average of $0.04. The stock has a market capitalization of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74.

Bellerophon Therapeutics Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 20th were issued a dividend of $0.019 per share. This represents a dividend yield of 117.8%. The ex-dividend date was Thursday, December 19th.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.